Discovery of Novel Sphingosine-1-Phosphate-1 Receptor Agonists for the Treatment of Multiple Sclerosis
作者:Sun Jun Park、Seul Ki Yeon、Yoowon Kim、Hyeon Jeong Kim、Siwon Kim、Jushin Kim、Ji Won Choi、Byungeun Kim、Elijah Hwejin Lee、Rium Kim、Seon Hee Seo、Jaeick Lee、Jun Woo Kim、Ha-Yeon Lee、Hayoung Hwang、Yong-Sun Bahn、Eunji Cheong、Jong-Hyun Park、Ki Duk Park
DOI:10.1021/acs.jmedchem.1c01979
日期:2022.2.24
The sphingosine-1-phosphate-1 (S1P1) receptor agonists have great potential for the treatment of multiple sclerosis (MS) because they can inhibit lymphocyte egress through receptor internalization. We designed and synthesized triazole and isoxazoline derivatives to discover a novel S1P1 agonist for MS treatment. Of the two scaffolds, the isoxazoline derivative was determined to have excellent in vitro
1-磷酸鞘氨醇 (S1P 1 ) 受体激动剂具有治疗多发性硬化症 (MS) 的巨大潜力,因为它们可以通过受体内化抑制淋巴细胞的排出。我们设计并合成了三唑和异恶唑啉衍生物,以发现一种用于 MS 治疗的新型 S1P 1激动剂。在这两种支架中,异恶唑啉衍生物被确定具有优异的体外疗效和药物样特性。其中,化合物21l被发现具有优异的药物样特性以及出色的体外功效(β-抑制蛋白募集中的EC 50 = 7.03 nM 和内化中的 EC 50 = 11.8 nM)。我们也确认了在实验性自身免疫性脑炎 MS 小鼠模型中, 21l有效抑制外周淋巴细胞计数试验中的淋巴细胞流出,显着提高了临床评分。